SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Evoq Remedies touches roof on receiving export order of Rs 136 crore

10 Jan 2024 Evaluate

EVOQ Remedies is currently trading at upper limit of Rs. 16.20, up by 2.70 points or 20.00% from its previous closing of Rs. 13.50 on the BSE.

The scrip opened at Rs. 14.70 and has touched a high and low of Rs. 16.20 and Rs. 14.70 respectively. So far 2124000 shares were traded on the counter.

The BSE group 'M' stock of face value Rs. 10 has touched a 52 week high of Rs. 18.49 on 19-Jun-2023 and a 52 week low of Rs. 10.50 on 16-Oct-2023.

Last one week high and low of the scrip stood at Rs. 16.20 and Rs. 13.37 respectively. The current market cap of the company is Rs. 22.03 crore.

The promoters holding in the company stood at 73.53%, while Non-Institutions held 26.47% stake in the company.

Evoq Remedies has received Export order of Rs 136 crore from the Marlexx Pharma Inc. to deliver high-quality pharmaceutical products and marks a significant step forward in its business growth. The order includes a range of pharmaceutical APIs namely Metformin API, Tramadol Hydrochloride API, Lisinopril API Powder, Omeprazole Powder API, Cefoxitin Sodium Sterile, Colistimethate Sodium Sterile, Meropenem Sterile and Pipracillin Sodium Sterile. 

Evoq Remedies is one of the recognized trading house of Pharmaceuticals Raw Materials, Excipients, Bulk Drugs at affordable price catering to the customers located in Ahmedabad.

EVOQ Remedies Share Price

3.49 0.10 (2.95%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Redington 234.90
Adani Enterprises 2218.35
Amrapali Industries 17.53
Rashi Peripheral 455.25
PDS 301.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×